Jun 11, 2020
Curis Announces $17.5 Million Registered Direct Offering
Jun 10, 2020
Curis Announces FDA Clearance of IND Application for CI-8993, the First-In-Class Monoclonal Anti-VISTA Antibody
May 12, 2020
Curis Reports First Quarter 2020 Financial Results
Apr 07, 2020
Curis to Present at 19th Annual Needham Virtual Healthcare Conference
Mar 12, 2020
Curis to Release Fourth Quarter and Year-End 2019 Financial Results and Hold Conference Call on March 19, 2020
Feb 27, 2020
Curis Announces $30 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
Feb 06, 2020
Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170
Jan 08, 2020
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 07, 2020
Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies
Dec 06, 2019
Curis Provides First-Ever Demonstration that Targeting IRAK4 in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Results in Anti-Cancer Activity in Ongoing Phase 1 Study
Dec 06, 2019
Curis Announces Positive Safety, Tolerability and Pharmacokinetic Data in Ongoing Phase 1 Study of Fimepinostat in Combination with Venetoclax
Nov 06, 2019
Curis Abstracts for Fimepinostat and CA-4948 Accepted for Presentation at the 61st Annual Meeting of the American Society of Hematology
Nov 05, 2019
Curis Reports Third Quarter 2019 Financial Results
Sep 26, 2019
Curis to Present at Cantor Fitzgerald Global Healthcare Conference
Jul 30, 2019
Curis to Release Second Quarter Financial Results and Hold Conference Call on August 6, 2019
Jul 05, 2019
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jun 12, 2019
Curis Highlights Publication in Nature Cell Biology Identifying Cancer-Causing Form of IRAK4 in Patients with AML and MDS
May 14, 2019
Curis Reports First Quarter 2019 Financial Results
May 06, 2019
Curis Completes Mesothelioma Enrollment in CA-170 Study
Feb 04, 2019
Curis, Inc. to Present at the 2019 BIO CEO & Investor Conference